Figure 4.

miR-92b increases proliferation, promotes cell-cycle progression, decreases apoptosis, and reduces chemosensitivity of cervical carcinoma cells. (a) The proliferation of CaSki cells with miR-92b mimics was greater versus cells with scrambled NC as determined by a CCK-8 assay. (b) The proliferation of SiHa cells with sh-miR-92b was lowered versus cells with scrambled NC as determined by a CCK-8 assay. (c) Morphological features of xenograft tumors in nude mice implanted with CaSki cells with sh-miR-92b or scrambled NC. Scale bar = 1 cm. (d) Xenograft tumor masses from nude mice implanted with sh-miR-92b CaSki cells were lower versus implanted CaSki cells with scrambled NC. (e) CaSki cells with miR-92b mimics exhibited lower proportion of cells in G0/G1 phase and greater proportion in S phase upon treatment with nocodazole. (f, g) CaSki and SiHa cells with sh-miR-92b elicited G0/G1 phase arrest upon treatment with nocodazole. (h–j) Apoptosis levels of (h) CaSki cells with miR-92b mimics and (i, j) CaSki and SiHa cells with sh-miR-92b were assessed by Annexin V-FITC/PI-based flow cytometry. (k–m) Caspase-3/7 activity was assessed in (k) CaSki cells with miR-92b mimics and (l, m) CaSki and SiHa cells with sh-miR-92b. (n–q) Chemosensitivity to cisplatin and paclitaxel was assessed in CaSki and SiHa cells with sh-miR-92b or scrambled NC.

Data are represented as means ± SEMs. *p < 0.05, **p < 0.01.

CCK-8, Cell Counting Kit-8; FITC, fluorescein isothiocyanate; NC, negative control; PI, propidium iodide; SEM, standard error of the mean.